ABVC
Price
$1.09
Change
-$0.00 (-0.00%)
Updated
Oct 29, 10:57 AM (EDT)
Capitalization
29.05M
One day until earnings call
Intraday BUY SELL Signals
CRSP
Price
$55.63
Change
+$1.52 (+2.81%)
Updated
Oct 29, 11:20 AM (EDT)
Capitalization
5.23B
11 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABVC vs CRSP

ABVC vs CRSP Comparison Chart in %
View a ticker or compare two or three
VS
ABVC vs. CRSP commentary
Oct 29, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABVC is a Hold and CRSP is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABVC with price predictions
Oct 28, 2026

ABVC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 15, 2026

ABVC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 41 cases where ABVC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ABVC as a result. In 70 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for ABVC just turned positive on October 22, 2026. Looking at past instances where ABVC's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.

ABVC moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ABVC crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +11.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABVC advanced for three days, in 197 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABVC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ABVC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.824) is normal, around the industry mean (3.151). P/E Ratio (-3.759) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (27.397) is also within normal values, averaging (439.237).

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. ABVC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABVC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for CRSP with price predictions
Oct 28, 2026

CRSP sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for CRSP moved above the 200-day moving average on September 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on CRSP as a result. In 80 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for CRSP just turned positive on October 28, 2026. Looking at past instances where CRSP's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.

Following a +10.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

CRSP moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

CRSP broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CRSP entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.996) is normal, around the industry mean (3.151). P/E Ratio (-11.488) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (439.237).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CRSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ABVC vs CRSP: Fundamental Ratings
ABVC
CRSP
OUTLOOK RATING
1..100
412
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
6258
P/E GROWTH RATING
1..100
2960
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (23) in the Biotechnology industry is in the same range as ABVC (41) in the null industry. This means that CRSP’s stock grew similarly to ABVC’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ABVC (100) in the null industry. This means that CRSP’s stock grew similarly to ABVC’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as ABVC (98) in the null industry. This means that CRSP’s stock grew similarly to ABVC’s over the last 12 months.

CRSP's Price Growth Rating (58) in the Biotechnology industry is in the same range as ABVC (62) in the null industry. This means that CRSP’s stock grew similarly to ABVC’s over the last 12 months.

ABVC's P/E Growth Rating (29) in the null industry is in the same range as CRSP (60) in the Biotechnology industry. This means that ABVC’s stock grew similarly to CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABVCCRSP
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 8 days ago
82%
Bullish Trend 1 day ago
82%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
75%
COMPARISON
Comparison
Oct 29, 2026
Stock price -- (ABVC: $1.09 vs. CRSP: $54.11)
Brand notoriety: ABVC and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABVC: 48% vs. CRSP: 79%
Market capitalization -- ABVC: $29.05M vs. CRSP: $5.23B
ABVC [@Biotechnology] is valued at $29.05M. CRSP’s [@Biotechnology] market capitalization is $5.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $134.26B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABVC’s FA Score shows that 1 FA rating(s) are green while CRSP’s FA Score has 1 green FA rating(s).

  • ABVC’s FA Score: 1 green, 4 red.
  • CRSP’s FA Score: 1 green, 4 red.
According to our system of comparison, ABVC is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABVC’s TA Score shows that 6 TA indicator(s) are bullish while CRSP’s TA Score has 4 bullish TA indicator(s).

  • ABVC’s TA Score: 6 bullish, 3 bearish.
  • CRSP’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ABVC is a better buy in the short-term than CRSP.

Price Growth

ABVC (@Biotechnology) experienced а +9.00% price change this week, while CRSP (@Biotechnology) price change was +7.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.21%. For the same industry, the average monthly price growth was -7.17%, and the average quarterly price growth was -10.71%.

Reported Earning Dates

ABVC is expected to report earnings on Oct 30, 2026.

CRSP is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (+8.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ABVC
Daily Signal:
Gain/Loss:
CRSP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EMDV47.88N/A
N/A
ProShares MSCI Emerging Markets Dividend Growers ETF (EMDV)
RILA12.36N/A
N/A
Indexperts Gorilla Aggressive Growth ETF (RILA)
CFA100.22-0.11
-0.11%
VictoryShares US 500 Volatility Wtd ETF (CFA)
MSSS36.21-0.20
-0.54%
Monarch Select Subsector ETF (MSSS)
ILF32.98-0.48
-1.43%
iShares Latin America 40 ETF (ILF)